Search results for Elotuzumab

Elotuzumab Biosimilar – Anti-SLAMF7, CD319 mAb – Research Grade, ProteoGenix, PX-TA1206

Description of Elotuzumab Biosimilar - Anti-SLAMF7, CD319 mAb - Research Grade Introduction Elotuzumab Biosimilar, also known as Anti-SLAMF7 or CD319 monoclonal antibody, is a research grade therapeutic antibody that is currently being studied for its potential use in the treatment of multiple myeloma. This antibody specifically targets the SLAMF7 protein, which is overexpressed in multiple myeloma cells, making it a promising therapeutic target. Structure of Elotuzumab Biosimilar Elotuzumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from human cells and has been modified to have a high affinity for SLAMF7. It is composed of two heavy chains and two light chains, each with a specific sequence of amino acids that determine its binding specificity. The antibody has a molecular weight of approximately 148 kDa and a half-life of 14 days. Mechanism of Action The primary mechanism of action of Elotuzumab Biosimilar is through its binding to SLAMF7 on the surface of multiple myeloma cells. This binding leads to the activation of natural killer (NK) cells and macrophages, which are part of the body’s immune system and play a crucial role in fighting cancer cells. The activated NK cells and macrophages then target and destroy the multiple myeloma cells, leading to tumor regression. Research and Clinical Trials Elotuzumab Biosimilar has been extensively studied in preclinical and clinical trials for its potential use in the treatment of multiple myeloma. In a phase I clinical trial, it was found to be well-tolerated and showed promising results in terms of its anti-tumor activity. Subsequent phase II and III trials have also shown significant improvements in progression-free survival and overall response rates when Elotuzumab Biosimilar was used in combination with other standard multiple myeloma therapies. Current and Potential Applications Currently, Elotuzumab Biosimilar is being investigated as a potential treatment for relapsed or refractory multiple myeloma, either as a monotherapy or in combination with other therapies. It has also shown promise in the treatment of newly diagnosed multiple myeloma, particularly in combination with lenalidomide and dexamethasone. In addition to multiple myeloma, Elotuzumab Biosimilar is also being studied for its potential use in other types of cancers, such as Waldenstrom macroglobulinemia and non-Hodgkin’s lymphoma, where SLAMF7 is also overexpressed. Conclusion In summary, Elotuzumab Biosimilar is a promising therapeutic antibody that specifically targets SLAMF7, a protein that is overexpressed in multiple myeloma cells. Its mechanism of action involves activating the body’s immune system to target and destroy cancer cells. With ongoing research and clinical trials, it has the potential to become a valuable treatment option for multiple myeloma and other cancers.

Elotuzumab, Kyinno, KB-1305

Elotuzumab, Abbexa, abx831163

Elotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SLAMF7/CD319, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148. 1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U. S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

Elotuzumab ELISA Kit, ProteoGenix, KPTX384

Description of Elotuzumab ELISA Kit Introduction Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule family member 7) protein, also known as CS1 (CD2 subset 1). This protein is highly expressed on the surface of multiple myeloma cells and is involved in the proliferation and survival of these cancerous cells. Elotuzumab has been approved by the FDA for the treatment of multiple myeloma in combination with other anti- cancer drugs. The development of the Elotuzumab ELISA Kit has enabled researchers to accurately measure the levels of this protein in biological samples, aiding in the understanding of its role in multiple myeloma and the effectiveness of Elotuzumab as a therapeutic target. Structure of Elotuzumab Elotuzumab is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 149 kDa. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the SLAMF7 protein, while the constant region is involved in effector functions such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. The humanization of Elotuzumab has reduced its immunogenicity, making it more suitable for therapeutic use. Mechanism of Action The primary mechanism of action of Elotuzumab is through its binding to the SLAMF7 protein on the surface of multiple myeloma cells. This binding leads to the activation of natural killer (NK) cells and macrophages, which then target and kill the cancerous cells. Elotuzumab also has a direct anti-proliferative effect on multiple myeloma cells by inhibiting the interaction between SLAMF7 and its ligand, CD47. This results in decreased survival and proliferation of the cancerous cells. Application of Elotuzumab ELISA Kit The Elotuzumab ELISA Kit is a valuable tool for researchers studying the role of SLAMF7 in multiple myeloma and the effectiveness of Elotuzumab as a therapeutic target. This kit allows for the accurate measurement of SLAMF7 levels in various biological samples, including serum, plasma, and cell lysates. It can also be used to quantify the amount of Elotuzumab in patient samples, providing information on drug levels and potential drug resistance. Therapeutic Target The development of Elotuzumab as a therapeutic target has shown promising results in the treatment of multiple myeloma. In clinical trials, the combination of Elotuzumab with other anti- cancer drugs has demonstrated improved outcomes, including increased progression-free survival and overall response rates, compared to standard therapy. Additionally, the use of Elotuzumab has shown a favorable safety profile, with minimal side effects reported. Research Use Besides its application in clinical settings, the Elotuzumab ELISA Kit has also been widely used in research studies. By accurately measuring SLAMF7 levels, researchers can better understand the role of this protein in multiple myeloma and its potential as a therapeutic target. The kit has also been used to investigate the relationship between SLAMF7 and other proteins involved in the pathogenesis of multiple myeloma, providing insights into potential combination therapies. Conclusion The development of the Elotuzumab ELISA Kit has been a crucial step in the study and treatment of multiple myeloma. This kit enables the accurate measurement of SLAMF7 levels, providing valuable information on its role in the disease and the effectiveness of Elotuzumab as a therapeutic target. With ongoing research and clinical trials, Elotuzumab has the potential to significantly improve outcomes for patients

Elotuzumab Biosimilar - Research Grade, ichor.bio, ICH5202

Detects SLAMF7

Research Grade Elotuzumab (HV217016), abinScience, HV217016